Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared a post on X:
“Fascinating Blood Advances re: MM plus secondary B-ALL – always tough.
Their approach: CD19/CD22 CAR-T followed by BCMA CAR-T chaser 24 hrs later
It worked for both cancers!!
But:
- Gr3 CRS, ICANS, IEC-HS. Decreased dose when combining?
- NB: 1st CAR will out-expand 2nd CAR.
Happy to see a positive outcome and such great correlatives here… “CARpools” with 2 separate products are being studied just as are traditional single-stalk dual-target CARs, and these results are fascinating.”
Title: Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL
Authors: Malte Roerden, Luca Hensen, Britta Besemer, Friederike Schwartz, Kristina Reuss, Alisha Weiss-Haug, Lennart Harland, Franziska Ginsberg, Christoph Faul, Wolfgang Bethge, Claudia Lengerke
Read the Full Article on Blood AdvancesÂ
More posts featuring Rahul Banerjee.
